🟢 20/20 Biolabs is trading 5% up in pre-market with no confirmed catalyst

20/20 Biolabs is trading 5.09% higher at $0.43 in pre-market, with no confirmed company-specific catalyst identified for the October 2 move.

• The latest company announcement was a September 29 notice of an October 7 investor webinar.
• The webinar will cover the FDA advisory committee discussion and the OneTest franchise model.
• Reported biotech-sector weakness does not align with the stock’s upward move.